AstraZeneca & Sanofi
14 shared events · Importance 3 · Last updated Sep 22, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
AstraZeneca: One of the nine signatories of the open letter urging the European Union to boost pharmaceutical investment and speed up trials. The appeal signals concern over European competitiveness but does not change its near-term financial outlook.
Sanofi: A signatory of the open letter calling on the European Union to boost pharmaceutical investment. The appeal reflects its concern about Europe lagging the United States and China in drug research and trials.
Sep 22, 2026 · 6 articles
Business
AstraZeneca: AstraZeneca licensed TQC3721, an inhaled PDE3/4 inhibitor for COPD, from Sino Biopharmaceutical in a deal valued up to US$1.9 billion. This strengthens AstraZeneca's respiratory pipeline and aligns with its focus on chronic diseases.
Sanofi: Sanofi is a key partner, having licensed rovadicitinib from Sino Biopharmaceutical in a deal valued up to US$1.53 billion. This adds a promising asset to Sanofi's pipeline, potentially enhancing its respiratory and immunology portfolio.
Jul 20, 2026 · 6 articles
Business
AstraZeneca: AstraZeneca is the primary developer and marketer of Tezspire. The successful trial could boost its pipeline credibility and support its $80 billion sales target by 2030, though shares were down slightly on the day.
Sanofi: Sanofi's Dupixent competes with Tezspire in severe asthma and potentially in eosinophilic esophagitis. Tezspire's success could increase competitive pressure on Dupixent.
Aug 27, 2026 · 6 articles
Business
AstraZeneca: AstraZeneca participated in the symposium, contributing to discussions on decarbonization and green chemistry.
Sanofi: Sanofi participated in the symposium, reflecting its interest in sustainable manufacturing technologies.
Jul 20, 2026 · 6 articles
Regulatory
AstraZeneca: AstraZeneca's flu vaccine portfolio could be affected by the entry of mFLUSIVA.
Sanofi: Sanofi's high-dose flu vaccine served as a comparator in trials; the new mRNA vaccine may compete with its products.
Aug 05, 2026 · 105 articles
Business
AstraZeneca: Listed among recent acquirers of radiopharmaceutical companies or assets, part of the consolidation wave that frames the Telix-ITM transaction.
Sanofi: Named among recent radiopharmaceutical acquirers, underscoring competitive pressure in the sector that motivates Telix's vertical integration.
Sep 21, 2026 · 6 articles
Regulatory
AstraZeneca: AstraZeneca is mentioned as a collaborator with Innate Pharma, specifically on the monalizumab antibody.
Sanofi: Sanofi is mentioned as a collaborator with Innate Pharma in immuno-oncology.
Apr 02, 2026 · 7 articles
Business
AstraZeneca: AstraZeneca is mentioned as a collaborator with Innate Pharma, specifically on the monalizumab antibody for non-small cell lung cancer.
Sanofi: Sanofi is mentioned as a collaborator with Innate Pharma, indicating existing partnerships in immuno-oncology.
Apr 08, 2026 · 6 articles
Business
AstraZeneca: Collaborator with Innate on monalizumab, mentioned as part of Innate's partnered assets, not directly affected by this deal.
Sanofi: Mentioned as a collaborator with Innate, not directly involved in this partnership.
Aug 10, 2026 · 10 articles
Regulatory
AstraZeneca: AstraZeneca is mentioned as a biopharmaceutical company with whom Innate Pharma has established collaborations, including the development of monalizumab.
Sanofi: Sanofi is mentioned as a biopharmaceutical company with whom Innate Pharma has established collaborations.
Apr 13, 2026 · 6 articles
Tech
AstraZeneca: Segev received honoraria; unrelated.
Sanofi: Segev received honoraria; unrelated to study.
Sep 04, 2026 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how AstraZeneca and Sanofi interact across events, view sentiment trends, and discover connected entities.
Open Dashboard